Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
|Videos|May 27, 2014
The Adoption of Robot-Assisted Surgery for Prostate Cancer
Author(s)Scott Eggener, MD
Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Translational and Outcomes Research, Section of Urology, University of Chicago, discusses the adoption of robot-assisted surgery and its impact on treatment patterns for newly diagnosed localized prostate cancer patients.
Advertisement
Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Translational and Outcomes Research, Section of Urology, University of Chicago, discusses the adoption of robot-assisted surgery and its impact on treatment patterns for newly diagnosed localized prostate cancer patients.
Clinical Pearls:
- There has been an increase in robot-assisted surgeries over the last 10 years
- Data from a study showed that when robotic surgery devices arrive in a town, more people in that town have surgery and less people have radiation therapy
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5